APA (7th ed.) Citation

Gainor, J., Curigliano, G., Kim, D., Lee, D. H., Besse, B., Baik, C. S., . . . Subbiah, V. (2021). Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. The lancet. Oncology, 22(7), . https://doi.org/10.1016/S1470-2045(21)00247-3

Chicago Style (17th ed.) Citation

Gainor, Justin, et al. "Pralsetinib for RET Fusion-positive Non-small-cell Lung Cancer (ARROW): A Multi-cohort, Open-label, Phase 1/2 Study." The Lancet. Oncology 22, no. 7 (2021). https://doi.org/10.1016/S1470-2045(21)00247-3.

MLA (9th ed.) Citation

Gainor, Justin, et al. "Pralsetinib for RET Fusion-positive Non-small-cell Lung Cancer (ARROW): A Multi-cohort, Open-label, Phase 1/2 Study." The Lancet. Oncology, vol. 22, no. 7, 2021, https://doi.org/10.1016/S1470-2045(21)00247-3.